Discover Great Companies Discover Great Clients
Popularity  13.5万   |   Followers  44   |   Likes  207   |   Feedback  36 Claim this company

Innovation for Life

No.73 Guangzhou City Popularity Ranking No.19 Huangpu District No.340 Guangdong No.1 Sheng Ming Ke Xue No.1 Innovative Drugs No.1 Antibodies No.1 Innovative Drugs Products No.1 Peptides No.1 Yuan Yan Yao No.1 Zhu She Liquids No.2 Yao Products R&D No.2 Pharmaceutical Technology No.2 Research Services No.2 Pharmaceutical R&D No.2 Biopharmaceuticals 自主创新示范企业 国家知识产权优势企业 省级专精特新中小企业 高新技术企业 省级高新技术企业 省级创新型中小企业
More

Company Overview

  • Nature: Listed Company Size: 1000-4999 employees Founded: 23年
  • Industry: Pharmaceuticals/Bioengineering 、 Raw Materials and Processing
  • Full name: Bio-Thera Solutions, Ltd.。

Development Stage

  • Stage: IPO上市, , 上交所。
  • Ranking: Ranked #73 in Guangzhou City by popularity Ranked #1 in Guangzhou Sheng Ming Ke Xue Company by popularity Ranked #1 in Guangzhou Innovative Drugs Company by popularity Ranked #1 in Guangzhou Antibodies Company by popularity Ranked #1 in Guangzhou Innovative Drugs Products Company by popularity
  • Honors: 2023中国企业慈善公益500强 2023中国高新技术企业慈善公益500强 自主创新示范企业 国家知识产权优势企业 According to algorithm
  • News: 2026-07-28:百奥泰:预计上半年净亏损2.3亿元-2.9亿元。
  • Salary: 48.6% of positions earn 10-20K, In 2026 vs last yeargrew by 14%.。Master's salary: ¥23.1K, Doctorate salary: ¥41.9K.
  • R&D: "Biology/Pharmaceutical/Chemical/Environmental Protection" demand: 38.3%, "Medical & Health/Beauty & Healthcare": 32.2%, "Other (R&D and Technical)": 17.9%。
  • Recruiting: In 2026 vs 2025grew by 4%. Demand for highly educated talent: Master's: 36, Doctorate: 17.
  • Requirement: Education: 本科 leads with 47.8%. Experience: 1-3年 leads with 39.6%.
  • Region: Distributed across 8 regions, 广州: 67.6%, 重庆: 3.4%, 北京: 2.7%, 武汉: 1.9%.

About the Company

[Summary] Innovation for Life

Bio-Thera is a global biopharmaceutical enterprise located in Guangzhou, China, grounded in science and innovation. The company is dedicated to developing next-generation innovative drugs and biosimilars for the treatment of tumors, autoimmune diseases, cardiovascular diseases, ophthalmic conditions, and other diseases that threaten human life or health. Committed to becoming a leading enterprise in the global development of antibody drugs, the company has already advanced multiple drugs to market approval. Among them, Betargin® (bevifibatide citrate) has been approved for marketing in China; adalimumab (UK trade name: Qletli®, China trade name: Geleli®) has been approved in China and the UK; tocilizumab (US trade name: TOFIDENCE™, China trade name: Shilirui®) has been approved in China, the US, the EU, Switzerland, and the UK; bevacizumab (trade names: Avzivi® in the US and EU, Pubeixi® in China, Bevyx® in Brazil) has been approved in China, the US, the EU, and Brazil; ustekinumab (US trade name: STARJEMZA™, European trade name: Usymro®) has been approved in the US, EU, and UK. Golimumab (European trade name: Gotenfia®) has been approved in Europe. TOFIDENCE™ has become the first monoclonal antibody drug developed and manufactured by a Chinese pharmaceutical company to receive FDA approval for marketing in the US. The company also has multiple candidate drugs in late-stage clinical trials, with a focus on tumor immunotherapy in the post-PD-1 era and antibody-drug conjugate (ADC) targeted drug development in the oncology field. Bio-Thera always prioritizes patient well-being as its core value, providing safe, effective, and affordable high-quality drugs through innovative research and development to meet urgent unmet therapeutic needs. For more information, please visit the official website or follow our Twitter and WeChat official account.

Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune diseases, cardiovascular diseases, eye diseases, and other severe unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next-generation antibody discovery and engineering, the company has advanced multiple candidates in late-stage development, including six approved products: QLETLI® (adalimumab) and BETAGRIN® (bevifibatide citrate) Injection in China, STARJEMZA® (ustekinumab) in the US, USYMRO® (ustekinumab) in the EU, Gotenfia® (golimumab) in the EU, TOFIDENCE® (tocilizumab) and AVZIVI® (bevacizumab-tnjn) in the US and EU, a/k/a POBEVCY® in China. In addition, the company has more than 20 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as antibody-drug conjugates (ADCs). For more information, please visit the official site or follow us on Twitter and WeChat (Bio-Thera).

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Bio-Thera Biologics Financing History (1 rounds)

Manage
IPO上市
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Market:
  • Deal: 上交所

Bio-Thera Biologics How Fast Is Hiring Growing? (173 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Up 51%
  • 2024: Up 6%
  • 2023: Up 58%
  • 2022: Down 49%
Bio-Thera Biologics Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
Bio-Thera Biologics Campus Recruitment & Advanced Degree Talent Demand
Interns 1 Master's 36 Doctorate 17
Note: How fast is hiring at Bio-Thera Solutions, Ltd. growing? Bio-Thera Biologics2026: 330 openings (up 4%), 2025: 318 openings (up 51%), 2024: 210 openings (up 6%), 2023: 199 openings (up 58%), 2022: 126 openings (down 49%), 2021: 248 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Bio-Thera Biologics Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Up 108%
  • 2024: Up 8%
  • 2023: Down 40%
  • 2022: Up 67%
Bio-Thera Biologics Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at Bio-Thera Solutions, Ltd. growing? Bio-Thera BiologicsMaster's recruitment over the years: 2025: 27 openings (up 108%), 2024: 13 openings (up 8%), 2023: 12 openings (down 40%), 2022: 20 openings (up 67%), 2021: 12 openings. Bio-Thera Biologics master talent ranking in Guangzhou: #52, Bio-Thera Biologics master salary mostly around 10-30K.

Bio-Thera Biologics Doctoral Degree Job Demand Analysis

(More)
+257%
Growth Rate
2026 vs 2025
  • 2025: Flat 0%-
  • 2024: Up 250%
  • 2023: Down 33%
  • 2022: Up 50%
Bio-Thera Biologics Doctoral Hiring by Year: 2026 — 18 more jobs than 2025
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at Bio-Thera Solutions, Ltd. growing? Bio-Thera BiologicsDoctorate recruitment over the years: 2026: 25 openings (up 257%), 2025: 7 openings (flat), 2024: 7 openings (up 250%), 2023: 2 openings (down 33%), 2022: 3 openings (up 50%), 2021: 2 openings. Bio-Thera Biologics doctorate talent ranking in Guangzhou: #28, Bio-Thera Biologics doctorate salary mostly around 30-50K and above.

Bio-Thera Biologics R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at Bio-Thera Solutions, Ltd.? Based on an analysis of Bio-Thera Biologics's job postings over the past year, "Biology/Pharmaceutical/Chemical/Environmental Protection" demand: 38.3%, "Medical & Health/Beauty & Healthcare": 32.2%, "Other (R&D and Technical)": 17.9%, "Computer/Network/Technology": 15%, "Scientific Research": 14%, "Mechanical/Instrumentation": 3.4%. For reference only.

Bio-Thera Biologics — What Are the Salaries Like? (413 records)

Manage
salary range: 6K - 50K, 48.6% of roles pay ¥10-20K
Note: salary statistics are based on 413 salary records from the past year and depend on the job sample. For reference only.
How is the salary at Bio-Thera Solutions, Ltd.?Bio-Thera Biologics48.6% of positions earn 10-20K, Fresh graduate salary: ¥9.0K。Guangzhou salary ranking top 30,生物/制药/化工/环保类 average salary ¥16.9K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of Bio-Thera Biologics

(More)
Are salaries high at Bio-Thera Solutions, Ltd.? We provide: 临床, Researcher, Information, RA, Analyst, 检验, Supervisor, Marketing, QC, QA, Senior Manager, Pharmaceutical Sales Representative, Cell Culture Specialist, Equipment Operator, Coordinator, Intern, Technology Development, Production Worker, Senior Director, Leasing Manager. Click to view detailed salary analysis by job.

Bio-Thera Biologics — Fortune 500? (More)

Yes, ranked in 中国企业慈善公益500强:

  • NO.352 2023中国企业慈善公益500强 >
  • NO.280 2022中国企业慈善公益500强 >
  • NO.401 2021中国企业慈善公益500强 >

Yes, ranked in 中国高新技术企业慈善公益500强:

  • NO.61 2023中国高新技术企业慈善公益500强 >
  • NO.52 2022中国高新技术企业慈善公益500强 >

Bio-Thera Biologics honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Job Category

  • 生物/制药/化工/环保类
    38.2% of total 38.2%
  • 医疗卫生/美容保健类
    32.1% of total 32.1%
  • 工厂生产类
    22.5% of total 22.5%
  • 销售类
    22.5% of total 22.5%

Education

  • 本科
    47.8% of total 47.8%
  • 大专
    18.1% of total 18.1%
  • 硕士
    14.3% of total 14.3%
  • 不限
    11.8% of total 11.8%

Experience

  • 1-3年
    39.6% of total 39.6%
  • 不限
    32.9% of total 32.9%
  • 3-5年
    15% of total 15%
  • 5-10年
    11.1% of total 11.1%
View Detailed Analysis

What does Bio-Thera Solutions, Ltd. require? Who is Bio-Thera Biologics hiring? Bio-Thera Biologics recruitment: 生物/制药/化工/环保类占比最多占38.2%,其次是医疗卫生/美容保健类占32.1%. What education can get in at Bio-Thera Biologics? 本科占比最多占47.8%,其次是大专占18.1%. High education required at Bio-Thera Biologics? 硕士占14.3%,博士占6.8%. Work experience required at Bio-Thera Biologics? 1-3年占比最多占39.6%,其次是不限占32.9%. Where are the job locations at Bio-Thera Biologics? 广州占比最多占67.6%,其次是重庆占3.4%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 41,408万(元)
Legal Representative: LI SHENGFENG(李胜峰)
Date Established:
Credit Code: 91440116751954446J
Registered Address: 广州市黄埔区国际生物岛螺旋二路18号

Partners & Suppliers

澎立生物为百奥泰提供临床前药效学评价服务 Source
供应商 制药企业
采购色谱填料用于阿达木单抗、贝伐珠单抗等生物类似药及创新药研发生产 Source
供应商 抗体药物
公司为其生物类似药提供CDMO服务 Source
供应商 重组蛋白与抗体药物
为其提供药物研发服务。 Source
供应商 生物大分子药物企业
获得百奥泰BAT2206(乌司奴单抗生物类似药)在欧盟、英国、瑞士、澳大利亚等地的独家商业化权益 Source
合作客户 产品权益授权合作

People who follow Bio-Thera Biologics also follow

Bio-Thera Biologics Competitors (Similar Companies)

试剂 化学制药 医药原料 生物医药
“Rapid test product R&D and manufacturer”
“One-stop full-process outsourcing services for drug and medical device”
“Ctrip in hand, travel at will”
“Inheriting the past, innovating for the future, providing good medicin”
方便面 茶饮料 饮品 碳酸饮料
换热器 汽车空调 家用空调 特种空调
“A large traditional Chinese medicine enterprise integrating R&D, produ”
淋浴房 金属建材 接插件 塑料注塑
“Executive director unit of China Printed Circuit Association, one of t”
电讯设备 液晶显示器 液晶显示/LCD 显示面板
生产 实业投资 售后服务 工业
“Jingke Electronics is a developer and manufacturer of LED packaging de”
制药/药业 原料药 盐酸 麻醉药
智慧城市 物联网/IoT 安防/安全防范 智慧交通

Discover Great Companies, Discover Great Clients

广州公司名录 广州“Huangpu District”公司名录 广州“制药/药业”公司名录 广州“生物科技/生物工程”公司名录 广州“药物研发”公司名录 广州“科研服务”公司名录 广州“多肽”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates